Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.30 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322074 | 0.96 | ASAH1 (0.33) | MAPTHTTALDH1A1ASAH1ACER2 | |
| SCHEMBL14590810 | 0.94 | NPSR1 (0.36) | MAPTHTTL3MBTL1ALDH1A1ASAH1 | |
| SCHEMBL6322560 | 0.93 | ASAH1 (0.39) | MAPTALDH1A1ASAH1ACER2CYP3A4 | |
| SCHEMBL5345145 | 0.93 | HTT (0.34) | HTTALDH1A1ASAH1ACER2CYP3A4 | |
| SCHEMBL5341797 | 0.93 | HTT (0.34) | HTTALDH1A1ASAH1ACER2CYP3A4 | |
| SCHEMBL7123674 | 0.92 | ASAH1 (0.40) | MAPTALDH1A1ASAH1ACER2CYP3A4 | |
| SCHEMBL6324729 | 0.92 | ASAH1 (0.40) | MAPTALDH1A1ASAH1ACER2CYP3A4 | |
| SCHEMBL6328123 | 0.92 | ASAH1 (0.40) | MAPTALDH1A1ASAH1ACER2CYP3A4 | |
| SCHEMBL6329147 | 0.92 | ASAH1 (0.40) | MAPTALDH1A1ASAH1ACER2CYP3A4 | |
| SCHEMBL6320903 | 0.92 | ASAH1 (0.40) | MAPTALDH1A1ASAH1ACER2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624306-B2 | Stabilizer for addition polymer | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-09-23 | — | — | US | claimed |
| US-20030166939-A1 | 2,2,6,6 diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | NESVADBA PETER (CH) | 2003-09-04 | — | — | US | claimed |
| US-20030065184-A1 | 2,2,6,6 diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | CIBA SPECIALTY CHEMICALS CORP. | 2003-04-03 | — | — | US | claimed |
| US-7160966-B2 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160966-B2 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160966-B2 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050143539-A1 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | NESVADBA PETER (CH) | 2005-06-30 | — | — | US | disclosed |
| US-6624306-B2 | Stabilizer for addition polymer | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-09-23 | — | — | US | disclosed |
| US-20030065184-A1 | 2,2,6,6 diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | CIBA SPECIALTY CHEMICALS CORP. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166939-A1 | 2,2,6,6 diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | ALKBH2, NFE2L2, DPYSL2 | MAPT 3356/4885HTT 3742/4885L3MBTL1 2282/4885 |
| US-20050143539-A1 | 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | ALKBH2, NFE2L2, DPYSL2 | MAPT 3356/4885HTT 3742/4885L3MBTL1 2282/4885 |
| US-20030065184-A1 | 2,2,6,6 diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides | ALKBH2, NFE2L2, DPYSL2 | MAPT 3356/4885HTT 3742/4885L3MBTL1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.